Benetou Despoina-Rafailia, Varlamos Charalampos, Pappas Christos, Kolokathis Fotios, Alexopoulos Dimitrios
Second Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens Medical School Athens, Greece.
US Cardiol. 2021 Oct 13;15:e17. doi: 10.15420/usc.2020.30. eCollection 2021.
Patients undergoing complex percutaneous coronary intervention (PCI) are at an increased risk of atherothrombotic complications. Although dual antiplatelet therapy is the mainstay of treatment for patients undergoing PCI with stent implantation, deciding its type and duration in complex PCI patients has long been considered a challenge for clinicians. This is because the beneficial effects of prolonged treatment and/or more potent antiplatelet agents' use in preventing ischemic events are hindered by a concomitant increase in bleeding complications. The aim of this review is to highlight current evidence regarding the optimal antithrombotic therapy regimens used in complex PCI patients, focusing on the evaluation of both safety and efficacy outcomes as well as addressing future perspectives.
接受复杂经皮冠状动脉介入治疗（PCI）的患者发生动脉粥样硬化血栓形成并发症的风险增加。尽管双重抗血小板治疗是接受支架植入PCI患者的主要治疗方法，但确定复杂PCI患者的治疗类型和持续时间长期以来一直被认为是临床医生面临的一项挑战。这是因为延长治疗和/或使用更强效抗血小板药物预防缺血事件的有益效果会因出血并发症的同时增加而受到阻碍。本综述的目的是强调有关复杂PCI患者使用的最佳抗栓治疗方案的当前证据，重点评估安全性和有效性结果以及探讨未来前景。
